Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations.

This year's 18th St. Gallen (SG) consensus conference on the treatment of early breast cancer (SGBCC: St. Gallen International Breast Cancer Conference) focused on practice-oriented questions. The individual situation and risk-benefit assessment were discussed in great detail. As in previous years, a German working group of leading breast cancer experts presented the results of the international SGBCC 2023 against the background of German treatment recommendations - especially the updated treatment recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) - for everyday clinical practice in Germany. The German treatment recommendations of AGO are based on the current evidence. The comparison with the clinical approach in Germany has proven useful, as the SGBCC panel consists of experts from different countries and disciplines. That is why country-specific characteristics can be incorporated into the SGBCC recommendations.

Informations de copyright

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

Déclaration de conflit d'intérêts

Conflict of Interest/Interessenkonflikt Prof. Michael Untch, MD: All remuneration to the AG/institution (referent and consultant activity): Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Lilly, MSD Merck, Myriad Genetics, Pfizer, Roche, Pierre Fabre, Novartis, Molecular Health, Agendia, GSK, Seagen, Gilead, Medac, Stemline Genzyme. Maggie Banys-Paluchowski, MD, Associate Professor, received remuneration from: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre, ExactSciences, Syantra, Stemline, and study support from: EndoMag, Mammotome, MeritMedical, Gilead, Hologic, ExactSciences, Sirius Medical. Prof. Sara Y. Brucker, MD, received remuneration from AstraZeneca, Roche, Novartis, Medtronic, Sanofi, Lilly, MSD, and Hologic. Prof. Wilfried Budach, MD, received remuneration from Merck, BMS, Jörg Eickeler Veranstaltungen, medpublico. Prof. Carsten Denkert, MD, received remuneration from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Merck, Molecular Health and study support from the European Commission, German Cancer Aid, BMBF, GBG, Myriad, and Roche. He is involved in patents for digital pathology (VMscope digital pathology software) and biomarker signatures (patents WO2015114146A1 and WO2010076322A1). Prof. Nina Ditsch, MD, received remuneration from AstraZeneca, Daiichi Sankyo, Gilead Sciences, Lilly, Merit Medical, Molecular Health, MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, Teva. Prof. Peter A. Fasching, MD, received grants from Biontech, Pfizer, Cepheid, and remuneration from Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Esai, Merck Sharp & Dohme, Lilly, Pierre Fabre, SeaGen, Roche, Agendia, Sanofi Aventis, Gilead, Mylan, and Menarini. Renate Haidinger has no conflicts of interest. Prof. Dr. med. Jörg Heil has no conflicts of interest. Prof. Dr. med. Christian Jackisch received remuneration from AstraZeneca, Lilly, Celgene, MSD; Eisai, Novartis, Pfizer, Gilead, Daiichi Sankyo, Medupdate, Streamed Up, Roche, and research support from Exact Sciences. Prof. Dr. med. Wolfgang Janni received remuneration from AstraZeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, ExactScience, GSK, Janssen, Lilly, Menarini, MSD, Novartis, Sanofi-Aventis, Roche, Pfizer, Seagen, Gilead, Inivata. Hans-Christian Kolberg, MD, Associate Professor, received remuneration from Pfizer, Novartis, Seagen, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, SurgVision, Onkowissen, Gilead, Daiichi Sankyo, and MSD, as well as travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro, and owns shares in Theraclion SA and Phaon Scientific GmbH. David Krug, MD, Associate Professor, received remuneration from Merck Sharp & Dohme, med update, onkowissen, and Pfizer, as well as research support from Merck KGaA. Prof. Dr. med. Sibylle Loibl did not receive any remuneration. The following companies granted support and remuneration to the GBG: Abbvie, Amgen; AZ; Celgene/BMS, Daiichi Sankyo, Gilead, GSK, Incyte, Lilly, MSD, Merck KG, Medupdate, Streamedup, Novartis, Olema, Pfizer; Relay, Sanofi, Seagen, Roche. Prof. Diana Lüftner, MD, received remuneration from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Gilead, GSK, high5md, Loreal, Novartis, onkowissen, Pfizer, Roche, Teva. Marion van Mackelenbergh, MD, Associate Professor, received remuneration from Amgen, AstraZeneca, Daiichi Sankyo, GenomicHealth, Gilead, GSK, Lilly, Molecular Health, MSD, Mylan, Novartis, Pfizer, PierreFabre, Roche, Seagen, and travel fees from Daiichi Sankyo, Gilead, Lilly. Prof. Julia Radosa, MD, received remuneration from Pfizer, Eisai, MSD, Medac GmbH, Roche, Novartis, Gedeon Richter, Lilly, Pierre Fabre, Daiichi Sankyo, Seagen, Theramex. Prof. Toralf Reimer received remuneration from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Myriad, Novartis, Pfizer, and Roche. Manfred Welslau, MD, received remuneration from Amgen, Astellas, AstraZeneca, Celgene, Gilead, Hexal, Janssen, Lilly, Novartis, Roche, Sanofi and has consulted and reviewed for Amgen, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, Medac, Novartis, Roche, Sanofi, AstraZeneca. Rachel Würstlein, MD, Associate Professor, received remuneration from Agendia, Amgen, Aristo, Astra Zeneca, Celgene, Clovis Oncology, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, GlaxoSmithKline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, PumaBiotechnology, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics/Seagen, Stemline, Tesaro Bio, Teva, Veracyte, Viatris, FOMF, Aurikamed, Clinsol, Pomme Med, medconcept, MCI. Prof. Nadia Harbeck, MD, received remuneration from Amgen, AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Sanofi, Seagen, Viatris, Zuelligpharma. Prof. Jens Huober, MD, received research support from Celgene, Novartis, Hexal, and Lilly. Remuneration for lectures from Lilly, Novartis, Roche, Pfizer, AstraZeneca, MSD, Celgene, Eisai, Abbvie, Seagen, Gilead, and Daiichi Sankyo. Consultancy fees from Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Daiichi, Gilead. Travel fees from Roche, Pfizer, Novartis, Celgene, Daiichi Sankyo, and Gilead. / Prof. Dr. med. Michael Untch: Alle Honorare an den AG/Institution (Referenten- und Beratertätigkeit): Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Lilly, MSD Merck, Myriad Genetics, Pfizer, Roche, Pierre Fabre, Novartis, Molecular Health, Agendia, GSK, Seagen, Gilead, Medac, Stemline Genzyme. PD Dr. med. Maggie Banys-Paluchowski erhielt Honorar von: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre, ExactSciences, Syantra, Stemline, und Studienunterstützung von: EndoMag, Mammotome, MeritMedical, Gilead, Hologic, ExactSciences, Sirius Medical. Prof. Dr. med. Sara Y. Brucker erhielt Honorar von AstraZeneca, Roche, Novartis, Medtronic, Sanofi, Lilly, MSD und Hologic. Prof. Dr. med. Wilfried Budach erhielt Honorar von Merck, BMS, Jörg Eickeler Veranstaltungen, medpublico. Prof. Dr. med. Carsten Denkert erhielt Honorar von Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Merck, Molecular Health und Studienunterstützung von der Europäischen Kommission, der Deutschen Krebshilfe, dem BMBF, der GBG, Myriad und Roche. Er ist an Patenten zur digitalen Pathologie (VMscope digital pathology software) und zu Biomarkersignaturen beteiligt (Patent WO2015114146A1 und WO2010076322A1). Prof. Dr. med. Nina Ditsch erhielt Honorar AstraZeneca, Daiichi Sankyo, Gilead Sciences, Lilly, Merit Medical, Molecular Health, MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, Teva. Prof. Dr. med. Peter A. Fasching erhielt Zuschüsse von Biontech, Pfizer, Cepheid sowie Honorar von Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Esai, Merck Sharp & Dohme, Lilly, Pierre Fabre, SeaGen, Roche, Agendia, Sanofi Aventis, Gilead, Mylan und Menarini. Renate Haidinger hat keine Interessenkonflikte. Prof. Dr. med. Jörg Heil hat keine Interessenkonflikte. Prof. Dr. med. Christian Jackisch erhielt Honorar von AstraZeneca, Lilly, Celgene, MSD; Eisai, Novartis, Pfizer, Gilead, Daiichi Sankyo, Medupdate, Streamed Up, Roche und Forschungsunterstützung von Exact Sciences. Prof. Dr. med. Wolfgang Janni erhielt Honorar von AstraZeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, ExactScience, GSK, Janssen, Lilly, Menarini, MSD, Novartis, Sanofi-Aventis, Roche, Pfizer, Seagen, Gilead, Inivata. PD Dr. med. Hans-Christian Kolberg erhielt Honorar von Pfizer, Novartis, Seagen, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, SurgVision, Onkowissen, Gilead, Daiichi Sankyo und MSD sowie Reisekostenunterstützung von Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro und besitzt Anteile von Theraclion SA and Phaon Scientific GmbH. PD Dr. med. David Krug erhielt Honorar von Merck Sharp & Dohme, med update, onkowissen und Pfizer sowie Forschungsunterstützung von Merck KGaA. Prof. Dr. med. Sibylle Loibl erhielt keine persönlichen Honorare. Unterstützung und Honorare an die GBG wurde von folgenden Firmen gewährt: Abbvie, Amgen; AZ; Celgene/BMS, Daiichi Sankyo, Gilead, GSK, Incyte, Lilly, MSD, Merck KG, Medupdate, Streamedup, Novartis, Olema, Pfizer; Relay, Sanofi, Seagen, Roche. Prof. Dr. med. Diana Lüftner erhielt Honoraria von Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Gilead, GSK, high5md, Loreal, Novartis, onkowissen, Pfizer, Roche und Teva. PD Dr. med. Marion van Mackelenbergh erhielt Honorar von Amgen, AstraZeneca, Daiichi Sankyo, GenomicHealth, Gilead, GSK, Lilly, Molecular Health, MSD, Mylan, Novartis, Pfizer, PierreFabre, Roche, Seagen sowie Reisekostenunterstützung von Daiichi Sankyo, Gilead, Lilly. Prof. Dr. med. Julia Radosa erhielt Honorar von Pfizer, Eisai, MSD, Medac GmbH, Roche, Novartis, Gedeon Richter, Lilly, Pierre Fabre, Daiichi Sankyo, Seagen, Theramex. Prof. Toralf Reimer erhielt Honorar von AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Myriad, Novartis, Pfizer und Roche. Dr. med. Manfred Welslau erhielt Honorar von Amgen, Astellas, AstraZeneca, Celgene, Gilead, Hexal, Janssen, Lilly, Novartis, Roche, Sanofi und hat Beratungs- bzw. Gutachtertätigkeit bei Amgen, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, Medac, Novartis, Roche, Sanofi, AstraZeneca. PD Dr. med. Rachel Würstlein erhielt Honorar von Agendia, Amgen, Aristo, AstraZeneca, Celgene, Clovis Oncology, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, GlaxoSmithKline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, PumaBiotechnology, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics/Seagen, Stemline, Tesaro Bio, Teva, Veracyte, Viatris, FOMF, Aurikamed, Clinsol, Pomme Med, medconcept, MCI. Prof. D. med. Nadia Harbeck erhielt Honorar von Amgen, AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Sanofi, Seagen, Viatris, Zuelligpharma. Prof. Dr. med. Jens Huober erhielt Forschungsunterstützung von Celgene, Novartis, Hexal, Lilly. Honorar für Vortragstätigkeiten von Lilly, Novartis, Roche, Pfizer, AstraZeneca, MSD, Celgene, Eisai, Abbvie, Seagen, Gilead, Daiichi Sankyo. Honorar für Beratertätigkeit von Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Daiichi, Gilead. Reisekostenunterstützung von Roche, Pfizer, Novartis, Celgene, Daiichi Sankyo, Gilead.